Articles published in Journal of Pharmacogenomics & Pharmacoproteomics have been cited by esteemed scholars and scientists all around the world. Journal of Pharmacogenomics & Pharmacoproteomics has got h-index 12, which means every article in Journal of Pharmacogenomics & Pharmacoproteomics has got 12 average citations.
Following are the list of articles that have cited the articles published in Journal of Pharmacogenomics & Pharmacoproteomics.
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Year wise published articles |
30 | 30 | 13 | 4 | 7 |
Year wise citations received |
59 | 69 | 60 | 48 | 62 |
Journal total citations count | 548 |
Journal Impact Factor | 2.31 |
Journal 5 years Impact Factor | 3.74 |
Journal CiteScore | 4.86 |
Journal h-index | 12 |
Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma
Ispitivanje zna?aja polimorfizama gena za citokine i proteine koji regulišu metabolizam i transport imunosupresivnih lekova u akutnom odbacivanju transplantiranog bubrega
Towards next-generation personalization of tacrolimus treatment: a review on advanced diagnostic and therapeutic approaches
CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy
Pharmacogenomics research and clinical implementation in Brazil
?????? ???????? Lancet ?? ???????? ??????????? ???????????? ???????? ? ??????????? ????????
The Lancet Commission on global mental health and sustainable development
Pioneering Function of Isl1 in Epigenetic Regulation During Second Heart Field Development
Differential CpG DNA methylation in peripheral naïve CD4+ T-cells in early rheumatoid arthritis patients
The Lancet Commission on global mental health and sustainable development
Análisis de los factores asociados a la susceptibilidad a fumar en estudiantes de educación secundaria del proyecto motiva educación secundaria del proyecto motivo EDUCA
Tobacco-You are never too Old to Quit
Pediatric Infectious Diseases
Quit Smoke or Quit Your Life With Stroke!
Alzheimer ’ s Disease and Glucose Metabolism
Novel indications for benzodiazepine antagonist flumazenil in GABA mediated pathological conditions of the central nervous system
Flumazenil for the treatment of refractory hypersomnolence: clinical experience with 153 patients
A study on the genetic polymorphisms of CYP3A5 among the Orang Asli in Malaysia using a next generation sequencing platform
In silico genetic variation analysis of cytochrome P450 2c19 and their effect in certain drugs metabolism
A study of CYP2C19* 2,* 3 and* 7 in different Sudanese ethnic groups and their response to omeprazole based triple therapy in Khartoum, Sudan 2016-2017.